


Ask a doctor about a prescription for Frimig
Sumatriptan
Each Frimig tablet contains a single dose of sumatriptan, which belongs to a group of medicines called triptans (also known as 5HT receptor agonists).
Frimig is used to treat migraine attacks with or without aura.
Migraine symptoms may be caused by temporary blood vessel dilation in the head. Sumatriptan is thought to reduce this dilation. This helps to eliminate headache pain and alleviate other migraine symptoms, such as nausea or vomiting and sensitivity to light and sound.
Before prescribing Frimig to a patient, the doctor will determine whether the patient's headache is caused by a migraine and not another condition.
Before taking Frimig, tell your doctor if any of the following apply to you:
Tell your doctor or pharmacist about all medicines you are taking now or have taken recently, as well as any medicines you plan to take. This includes any herbal preparations, dietary supplements such as vitamins, iron, or calcium, and medicines you have bought without a prescription.
Some medicines must not be taken with Frimig, and others may cause side effects if taken with Frimig. Tell your doctor if you are taking:
Stop taking these medicines at least 24 hours before starting Frimig. Do not take them again for at least 6 hours after stopping Frimig.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy:
If you are pregnant or think you may be pregnant, tell your doctor before taking Frimig. Experience with the use of Frimig during pregnancy is limited. So far, available data do not indicate an increased risk of birth defects. Discuss with your doctor whether you can take Frimig during pregnancy.
Breastfeeding:
Do not breastfeed your baby for 12 hours after taking Frimig. Express milk during this time and discard it. Do not give it to your baby.
Migraine symptoms or the medicine may cause drowsiness. If this occurs, do not drive or operate machinery.
Frimig contains lactose.
This medicine contains 176.3 mg of lactose in a 50 mg tablet and 352.6 mg of lactose in a 100 mg tablet.
If you have been told that you have an intolerance to some sugars, contact your doctor before taking this medicine.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means it is essentially 'sodium-free'.
Always take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
Take these tablets as soon as you feel that a migraine attack is coming, although you can take them at any time during an attack.
Do not take Frimig to prevent a migraine attack - only take it after migraine symptoms appear.
Adults
The recommended dose is one 50 mg tablet, swallowed whole with water.
Some patients may need a 100 mg dose - follow your doctor's instructions.
Children and adolescents under 18 years
Frimig is not recommended for children under 18 years.Elderly patients (over 65 years)
Frimig is not recommended for patients over 65 years.
You can take another Frimig tablet only if it has been at least 2 hours since you took the previous tablet. Do not take more than 300 mg in total in 24 hours.
Do not take a second tablet or any other sumatriptan-containing medicine during the same attack. If there is no improvement after taking one tablet, you can take other painkillers such as paracetamol, acetylsalicylic acid, or non-steroidal anti-inflammatory drugs. You can take Frimig again during the next attack. If Frimig does not relieve your symptoms, ask your doctor for advice.
Do not take more than six 50 mg tablets or three 100 mg tablets (a total of 300 mg) in 24 hours. Taking too much Frimig may cause illness. The symptoms of overdose are the same as those listed in section 4 "Possible side effects". If you or someone else has taken too many tablets, contact a doctor, hospital, or the Poison Information Centre.
Like all medicines, Frimig can cause side effects, although not everybody gets them.
Frequency not known (frequency cannot be estimated from the available data):
Skin allergic reactions: skin rashes, such as red spots or hives.
Anaphylaxis (severe allergic reactions, such as swelling of the eyelids, face, or lips, and sudden wheezing, uneven heartbeat, chest pressure, or collapse).
If you experience any allergic reactions, stop taking Frimigand seek medical help immediatelyif the reactions are severe.
Common (may affect up to 1 in 10 people):
Very rare (may affect up to 1 in 10,000 people):
Frequency not known (frequency cannot be estimated from the available data):
If you experience any side effects, including any not listed in this leaflet, tell your doctor or pharmacist.
If you experience any side effects, including any not listed in this leaflet, tell your doctor, pharmacist, or nurse. You can also report side effects directly to the Pharmacovigilance Department, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: 22 49-21-301, fax: 22 49-21-309, website: https://smz.ezdrowie.gov.pl
You can also report side effects to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the carton.
The expiry date refers to the last day of the month.
Do not store above 25°C. Store in the original package.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
50 mg coated tablet:
Round, white, coated tablets with "RDY" engraved on one side and "292" on the other.
100 mg coated tablet:
White, capsule-shaped, coated tablets with "RDY" engraved on one side and "293" on the other.
Both strengths are available in blisters in cartons of 2, 3, 4, 6, 12, and 18 tablets.
Not all pack sizes may be marketed.
Orion Corporation
Orionintie 1
FI-02200 Espoo
Finland
Orion Corporation, Orion Pharma
Orionintie 1
FI-02200 Espoo
Finland
Orion Corporation, Orion Pharma
Joensuunkatu 7
FI-24100 Salo
Finland
To obtain more detailed information on this medicine, contact the local representative of the marketing authorization holder:
Orion Pharma Poland Sp. z o.o.
[email protected]
Finland, Sweden:
Oriptan
Poland, Czech Republic:
Frimig
Hungary:
Sumatriptan Orion
Date of last revision of the leaflet:01.02.2022
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Frimig – subject to medical assessment and local rules.